# A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

> **NCT05348915** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 242 (actual)

## Conditions studied

- Sickle Cell Disease
- Vaso-occlusive Crisis
- Vaso-occlusive Pain Episode in Sickle Cell Disease

## Interventions

- **DRUG:** Inclacumab

## Key facts

- **NCT ID:** NCT05348915
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2025-11-07
- **Final completion:** 2025-11-07
- **Target enrollment:** 242 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study based on results of parent study GBT2104-131.
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348915, "A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05348915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*